ZimVieZIMV
ZIMV
About: ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
Employees: 1,770
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
57% more call options, than puts
Call options by funds: $191K | Put options by funds: $122K
2.07% less ownership
Funds ownership: 85.26% [Q4 2024] → 83.19% (-2.07%) [Q1 2025]
4% less funds holding
Funds holding: 268 [Q4 2024] → 256 (-12) [Q1 2025]
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
24% less capital invested
Capital invested by funds: $328M [Q4 2024] → $249M (-$79.6M) [Q1 2025]
25% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 69
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
47%
downside
Avg. target
$14.50
23%
downside
High target
$19
1%
upside
2 analyst ratings
0 positive
0%
2 neutral
100%
0 negative
0%
Barclays Matt Miksic | 1%upside $19 | Equal-Weight Upgraded | 22 Jul 2025 |
UBS Kevin Caliendo | 47%downside $10 | Neutral Maintained | 15 May 2025 |
Financial journalist opinion
Based on 9 articles about ZIMV published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025
PALM BEACH GARDENS, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025.
Neutral
GlobeNewsWire
6 days ago
ZimVie Announces Exclusive Distribution Agreement with Osstem Implant to Expand Premium Dental Implant Offering in China
PALM BEACH GARDENS, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced a strategic distribution agreement with Osstem Implant Co., Ltd.
Neutral
Business Wire
1 week ago
ZIMVIE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ZimVie Inc. - ZIMV
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ZimVie Inc. (NasdaqGS: ZIMV) to an affiliate of ARCHIMED. Under the terms of the proposed transaction, shareholders of ZimVie will receive $19.00 in cash for each share of ZimVie that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, o.
Neutral
GlobeNewsWire
1 week ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Neutral
GlobeNewsWire
1 week ago
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of ZimVie Inc. (NASDAQ: ZIMV)
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating ZimVie Inc. (NASDAQ: ZIMV ) related to its sale to an affiliate of ARCHIMED. Under the terms of the proposed transaction, ZimVie shareholders will receive $19.00 in cash per share. Is it a fair deal?
Neutral
Investors Business Daily
1 week ago
ZimVie Doubles — And Then Some — On Its Second Takeover Deal
ZimVie shares catapulted by triple digits Monday after the dental implant maker agreed to a $730 million takeover deal.
Neutral
PRNewsWire
1 week ago
Shareholder Alert: The Ademi Firm investigates whether ZimVie Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE , July 21, 2025 /PRNewswire/ -- The Ademi Firm is investigating ZimVie (NASDAQ: ZIMV) for possible breaches of fiduciary duty and other violations of law in its transaction with ARCHIMED. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
Neutral
Business Wire
1 week ago
ZIMV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ZimVie Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ZimVie Inc. (NASDAQ: ZIMV) to an affiliate of ARCHIMED for $19.00 in cash per share is fair to ZimVie shareholders. Halper Sadeh encourages ZimVie shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether ZimVie and its.
Neutral
GlobeNewsWire
1 week ago
ZimVie Announces Definitive Agreement to be Acquired by ARCHIMED for $19.00 Per Share in Cash
PALM BEACH GARDENS, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (“ZimVie”) (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced their entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”), an investment firm focused exclusively on healthcare industries.
Positive
Seeking Alpha
1 month ago
ZimVie: Screening Cheap (Rating Upgrade)
ZimVie's stock has plunged over 40% since my downgrade, but recent cost reductions are improving profitability, and the stock is forming a bottoming pattern. Despite continued revenue declines, especially internationally, EBITDA margins have expanded and full-year guidance remains achievable. Valuation is now attractive, with ZIMV trading at a significant discount to dental implant peers on a Fwd EV/EBITDA basis.
Charts implemented using Lightweight Charts™